Background. Viscosupplementation (VS) is a symptomatic treatment of knee osteoarthritis. although systematic reviews of its repeat use showed favorable benefit/risk ratio, no study has focused on the indication of retreatment. Methods. a task force was created to look at issues regarding retreatment with VS in knee osteoarthritis. an attempt was made to reach consensus on several issues: (1) to define treatment "success" and "failure," (2) to determine when to retreat patients successfully treated by a previous VS, (3) to determine how to retreat patients in whom VS failed, (4) to define what to do in case of adverse reaction following previous VS, and (5) to examine the interests of soluble biomarkers to manage retreatment. after debate and review of literature the working group voted on 88 issues. two "decision trees" were built based on the results of the votes. Results. in case of failure, the authors draw attention to the need of a rigorous clinical and radiological analysis, and consider evidence-based medicine. When VS was previously successful, retreatment can be considered after recurrence or increase in pain. However, in subjects with high risk of disease progression, in young patients, and in professional sportsmen, retreatment could be considered systematically, because of the probability of hyaluronic acid to slow osteoarthritis progression. evidence on soluble biomarkers was not considered as enough strong to support their use as decision tools for patient retreatment. Conclusion. the decision algorithms are intended to facilitate consideration of the therapeutic options, in patients with knee osteoarthritis previously treated with VS.
Osteoarthritis
Current recommendations for the treatment of knee osteoarthritis (OA) include a combination of nonpharmacological and pharmacological modalities. [1] [2] [3] [4] Among the latter, viscosupplementation (VS) by intra-articular (IA) injection(s) of hyaluronic acid (HA) 5 are aimed to reduce pain and to improve joint function, through complex mechanical and biological mechanisms that might restore joint homeostasis. 6 VS is recommended by some scientific societies, in patients with knee OA where pain is not adequately relieved with conventional therapy. [7] [8] [9] [10] Recent meta-analysis and systematic reviews of randomized controlled trials (level of evidence 1) have ranked VS among the most effective treatments to relieve pain in patients with mild to moderate knee OA. 11, 12 Furthermore in some studies, patients perceived VS as the most effective treatment for knee OA 13 whereas other level of evidence-1 studies showed controversial results regarding VS efficacy. 14, 15 Recently, 3 studies have demonstrated that HA decreased the serum or urine levels of soluble biomarkers reflecting cartilage metabolism. [16] [17] [18] Nonetheless it is not known whether HA elicits an indirect reaction on the articular metabolism secondary to an increased use of the joint due to its analgesic effect or through a direct action on the cartilage metabolism. 19 These finding suggested that some soluble biomarkers could be used as an indicator for HA reinjection. 
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Decision Algorithms for the Retreatment with Viscosupplementation in Patients Suffering from Knee Osteoarthritis: Recommendations from the EUROpean VIScosupplementation COnsensus Group (EUROVISCO)
In 2014, the EUROpean VIScosupplementation COnsensus working group (EUROVISCO) proposed a set of recommendations for the use of VS, based on both an extensive research of the literature and experts' opinion. 19 A consensus position was obtained for 16 of the 24 statements discussed, allowing to establish clear recommendations to help practitioners using VS.
In September 2015, the same group, expanded with 3 further experts, congregated to propose algorithms for the management knee OA patients, previously treated with VS.
The experts have examined 2 situations: (1) the reinjection in patients successfully treated with VS, 6 to 12 months ago and (2) the reinjection in patients where previous VS failed or caused adverse reactions. Finally, the experts discussed the interests and limits of using soluble biomarkers in the decision of VS retreatment.
Methods
experts
Ten experts from Belgium, France, Germany, Italy, Spain, and the United Kingdom, congregated in a working group meeting held in Lyon, France, on September 17-18, 2015 . This expert panel constituted of 7 rheumatologists, 2 orthopaedic surgeons, and 1 physiotherapist. All had expertise in clinical research methodology in the field of OA and VS and experience in academic medicine and/or private practice.
issues Three members of the task force (RR, TC, YH) were tasked to collate an exhaustive literature analysis on the topic. Eighteen statements were discussed during the meeting. After extensive debate, the expert panel had to give opinion on each of the 88 issues within the 18 statements. The first step was to define "success" and "failure" of the treatment. The second step was to determine when and how to retreat patients successfully treated by a previous VS. The third step was to determine when and how to retreat patients in whom VS previously failed. The fourth step was to propose management options where the patient experienced moderate adverse reaction following previous VS. Finally, the task force examined the role of serum and urine biomarkers in retreatment with HA.
Scoring and Voting Methods
For each statement, the experts had to score according to their degree of agreement, using a 4-point Likert-type scale (0-3), with 0 = "I don't agree," 1 = "I tend to disagree," 2 = "I tend to agree," and 3 = "I agree." After debate and review of literature, each item was finally classified into 2 categories: "Agree" or "Disagree." The statement was adopted and was consequently included into the decision algorithm only if 8 experts or more voted either to "Agree" or "Disagree." At the end of the session, 2 "Decision Trees" regarding retreatment with VS were built according to the results of the votes: one after failure and the second after success of a previous VS.
Recommendations
The algorithms of recommendations ( Figs. 1 and 2) were drafted by 1 expert (TC) after taking into account suggestions, comments, and approval of all the experts in the working group The decision trees presented in the present guidelines are intended to facilitate consideration of the therapeutic options in patients with knee OA previously treated with VS.
Issues
Definition of treatment Failure
Viscosupplementation is aimed to alleviate pain and decrease disability in patients suffering from knee OA "not sufficiently improved" by the first-line treatments, including analgesics and nonpharmacological modalities. 1, 4 However, the definition of "sufficiently" improved remains unclear. The practitioner is faced with this several times a day, before a treatment decision is made. The optimal duration of efficacy is yet to be defined. Compared with IA corticosteroids, HA injections have a delayed onset of action. They are more effective in the long term, up to 26 weeks. 20 Some studies have demonstrated that VS might be effective up to 1 year. 21, 22 So the task force agreed that duration of efficacy should not be less than 6 months.
To define the concept of treatment failure, the panel of experts had to answer the following issues: 
Retreatment of Patients Successfully treated by Previous VS
The following issues were discussed when re-treating patients who improved with previous VS: 
Retreatment of Patients with Moderate adverse Reaction after Previous VS
The task force agreed on a management plan in patients who experienced a mild to moderate adverse reaction, such as increase of pain, swelling, and synovial effusion after a previous VS. The questions analyzed were:
1. 
interests and limits of Soluble Biomarkers for Managing Retreatment with Ha
Four issues were debated on the value of serum and urine biomarkers for the decision of retreatment with VS:
Results
Definition of treatment Failure
Agreement and level of consensus are summarized in Table 1 .
To define the failure of treatment, the working group overwhelmingly endorsed the concept of PASS. 24 It stressed that PASS, defined as the value beyond which patients consider themselves well (i.e., 4 on a 10-point rating scale), 24 is a clinically relevant outcome for the patient. Asking the question "Are you feeling good" is much more relevant to assess the treatment efficacy in daily practice than the question "Are you feeling better," 24, 29 that can be assessed using MCII, defined as the smallest change in measurement that signifies an important improvement in a patient's symptom. 24 The patient's opinion being the primary concern, the experts, emphasized the concept of "patient's satisfaction" with respect to the treatment regardless of the results of PASS and MCII. However a decrease of pain inferior to MCII threshold (−2 points and 20% on a 10-point rating scale) 24 was also rated as treatment failure by 8 out of the 10 experts. Among the main tools for assessing treatment's success or failure, only the patient's overall opinion and PASS were rated as useful in clinical practice, whereas all others were considered useful in clinical trials. 
issues on Retreatment after Success of Previous Viscosupplementation
Agreement and level of consensus are summarized in Table 2 .
There was a strong level of consensus to re-treat patients as soon as pain occurs again and not to retreat asymptomatic or minimally symptomatic patients systematically. In the latter case, there was a consensus to adapt the frequency of treatment to patients' individual situation. PASS threshold 24 was also rated to be a useful tool in the decision of retreatment. A large majority of the experts identified 4 clinical situations that can potentially persuade physicians to retreat patients sooner: early stage of OA, young age, risks factors of progression and professional sportsperson. Severe comorbidities that contra indicate NSAIDs and surgery were also considered as arguments in favor of an earlier retreatment. Most experts acknowledge being influenced by the results of studies intended to demonstrate the chondroprotective properties of HA.
issues on Retreatment after Failure of Previous Viscosupplementation
Agreement and level of consensus are summarized in Table 3 .
Among the main reasons for VS failure, 4 have obtained a unanimous vote: wrong clinical analysis of the pain origin, extra-articular injection(s), obesity and radiographic KL grade IV. Severe femoropatellar involvement, pain due to meniscus tear, OA flare, isolated patellofemoral involvement, inappropriate protocol, inaccurate analysis of anatomical severity were also considered as predictive factors of VS failure by most of the experts.
issues on Retreatment after adverse Reaction with Previous Viscosupplementation
Agreement and level of consensus are summarized in Table 4 .
Eight out of the 10 experts advised to change the viscosupplement and/or the injection protocol in case of a nonserious local adverse reaction at index course of VS. Adding an IA corticosteroid or choosing another viscosupplement (i.e., biofermentative instead of animal origin) were the 2 main proposals but opinions were divided and no consensus was obtained.
issues on Viscosupplementation and techniques of injection
Agreement and level of consensus are summarized in Table 5 . A consensus was reached on the assertion that viscosupplements must be used in accordance with recommendations based on scientific evidence. Thus, all the group members agreed that any single injection regimen should only use crosslinked HA. A large majority of them agreed with the fact that only repeat injections can be effective when cross-linked HA is used. A strong agreement was obtained on the differences between viscosupplements that can have an impact on the clinical result: injected volume, molecular structure, and molecular weight were the items that obtained the highest level of agreement. To ensure IA delivery of HA, the group stressed the importance of synovial fluid aspiration, lateral mid-patellar route approach and physician experience. Surprisingly, only a moderate consensus was obtained for the use of imaging guidance.
Finally, the experts have considered it not necessary to perform X-rays before any new course of injection. There was overall agreement on the uselessness to perform routine MRI or ultrasonography before any new treatment.
issues on interests and limits of Soluble Biomarkers for Managing Retreatment with Ha
Agreement and level of consensus are summarized in Table 6 . Ha = hyaluronic acid; VS = viscosupplementation; Oa = osteoarthritis; Mri = magnetic resonance imaging.
The experts were almost unanimous to consider that effect of viscosupplementation on cartilage metabolism is a valuable outcome in the follow-up of OA patient. However, analyzing the current evidence in the literature, it was agreed that there is not enough evidence to support the use of soluble biomarkers as indicator of HA re-injection or for monitoring the effects treatment in the daily practice. However, they recommend the use of biomarkers in clinical trials to monitor the effect of VS on joint tissue metabolism.
Discussion
Several studies have been conducted to investigate safety and efficacy of retreatment with IA hyaluronans. [30] [31] [32] [33] Repeat courses of the hyaluronans have been shown to be safe and effective in the treatment of pain associated with OA of the knee. 30 A multicenter, randomized, controlled study in 306 patients with knee who received 4 cycles of 5 IA HA or placebo injections suggested that HA repeat injections not only improve knee OA symptoms during the in-between cycle period, but also exert a marked carry-over effect for at least 1 year after the last injections. 22 Altman et al. 31 showed that repeat IA injections of BioHA (2 cycles of 3 injections at 6 month interval) were effective, well tolerated, and not associated with an increase in adverse events, such as synovial effusions. Patients not only maintained their improvement from baseline but also experienced an additional pain score decrease after the second cycle of injections. Comparable favorable results were obtained after repeat injections of a single injection of a biofermentative crosslinked HA. 32 On the opposite, a retrospective study of patients who received multiple courses of 3 weekly Hylan G-F 20 injections showed that the incidence of local adverse reactions tended to increase with subsequent courses of therapy. 33 However, so far, no work has been published about indications of retreatment with HA therapy. The purpose of the meeting was to consider all the factors that can influence, positively or negatively, a doctor's decision to retreat patients with HA and also to build a decisional algorithm. The first part of the work emphasizes the importance of the patient's opinion in the therapeutic decision, particularly in the definition of treatment failure or success. The task force highlighted the importance of PASS and patient's satisfaction in the assessment of VS efficacy. On the contrary, composite indices (WOMAC, KOOS, and OMERACT-OARSI criteria) were not considered as useful in daily practice, but remained as valuable tools in clinical trials. Although useful for assessing the overall impact of the disease on daily activities, these indices do not necessarily reflect the real perception of the patients. Pain on nominated activity has been shown to be at least as, and in some cases more, sensitive to change than the KOOS/WOMAC questionnaire. 34 In patients not satisfied with previous VS, several predictors of treatment failure have been identified. The unanimously identified factors were a wrong clinical analysis of pain and the extra-articular delivery of the HA. Indeed, the high disparity between the radiographic structural damage and the severity of symptoms in knee OA patients implies the prominent role of other factors than the joint pathology itself. 35 Among the mechanisms of pain in OA, peripheral and central sensitizations, meniscus lesions, subchondral bone microcracks and inflammatory mechanisms, have been suggested to be of great importance. 35, 36, 37 Despite the diversity, HA exhibits various and complex mechanisms that can explain its efficacy to alleviate OA pain (mild anti-inflammatory effect, analgesic actions, effect on subchondral bone, increase of glycosaminoglycan synthesis, inhibition of several matrix metalloproteinases). 37 It is likely that HA cannot act, with the same efficiency, on all the elements resulting in OA pain. Other studies have shown that obesity and very severe joint space narrowing were predictors of VS failure. 38 Interestingly, based on their own experience, most of the experts considered patellofemoral OA (isolated or severe) as a predictor of VS failure, despite the lack of evidence in the literature. 39, 40 Before taking the decision to retreat with HA in patients where VS failed, the first step in the decision tree ( Fig. 1) , is to confirm the appropriate indication: evidence of OA, no other cause of knee pain (osteonecrosis, tendonitis, inflammatory or septic arthritis, microcrystal deposition disease, pain due to meniscus extrusion, complex regional pain syndrome), no OA flare or severe neuropathic pain. If indication is incorrect do not repeat HA injections and the instead change to a more appropriate treatment by choosing one more adapted to the clinical situation (i.e., IA corticosteroids in case of flare-up with synovial fluid effusion, injection of corticosteroids into the meniscus wall or arthroscopic meniscus repair if pain due to meniscus lesion, knee arthroplasty in case of advanced OA, pregabalin or duloxetine in case of neuropathic pain, weight loss program or bariatric surgery in case of obesity, etc., to name a few). If the indication was correct but with concomitant one or several predictive factors of failure, the working group recommends to discuss other treatment options with the patient after explaining that the chances of success of a new or repeat VS is low. 38 If indication is correct and there are no major predictive factors of failure, one should confirm, "Whether the treatment was properly administered?" (i.e., number of injections, volume injected, interval between injections, in agreement with the product recommendations as described on the products' SmPC [Summary of Product Characteristics]). Indeed, any new dosing regimen should be supported by controlled versus comparator or placebo trials. 19 In this way, a randomized prospective trial comparing 2 different dosages of an intermediate-molecular-weight linear HA (3 × 2 mL weekly injections vs. one 6 mL injection), has demonstrated that a 3-weekly injection regimen was more effective than a single 6 mL injection. 41 The choice of viscosupplement is also subject to debate and controversies regarding possible differences of efficacy between marketed viscosupplements, related to their molecular weight, origin, or extraction mode. There was only a moderate level of agreement between the experts of the task force while considering the choice of the viscosupplement as a predictor of clinical result despite a recent review reporting that high-molecular-weight HA was superior to lower molecular weight HA products and that HA obtained through biofermentation process had a better safety profile than avian-derived HA products. 37 After ensuring the HA is administered as protocol, we must guarantee that viscosupplement has been administered intra-articularly. It is often difficult to be sure, except in case of synovial fluid aspiration during the procedure and where imaging guidance was used. The working group felt that ultrasound or fluoroscopy guidance is indispensable in IA injections to deep or small joints, such as the hip and trapeziometacarpal joints. However, a good knowledge of the injection techniques and anatomy allows for IA injection without imaging guidance in the knee. The lack of pain during injection does not guarantee the correct placement of the needle into the IA space, but a painful injection is usually a sign of an extraarticular injection. Debate continues on the "best" approach portal for knee injection. 42, 43 On this topic, the working group had a consensual point of view, admitting that no approach was 100% accurate, but lateral mid-patellar approach had to be preferred to the anterior approaches 16 due to improved accuracy. [42] [43] [44] The task force also stressed the importance of the physician experience in IA injection techniques. If all precautions have been taken to ensure optimal IA injection and the treatment failed, it must be concluded not to try new or repeat VS and change therapeutic option. The algorithm details are given in Figure 1 .
Another very frequent clinical scenario is a patient, who significantly improved with VS, and returns to follow-up, 6 to 12 months later. Four different case scenarios can be identified-(1) the patient remains "symptom free," (2) the patient remains "minimally symptomatic" but with no increasing pain, (3) the patient is "minimally symptomatic" but with increasing pain, or (4) the patient is symptomatic again. In the first situation, the task force did not recommend to retreat systematically. Consequently, there was a strong agreement to advise retreatment as soon as the pain recurs and if pain exceed the PASS threshold. In "minimally symptomatic" patients with no increase of pain, the EUROVISCO group members proposed to retreat young patients, early stages of OA, patients with risk factors of progression, [45] [46] [47] [48] [49] professional sportsmen and patients with severe comorbidities. One expect to benefit of potential protective effect of viscosupplement, and then prevent OA onset or progression. Those patients at high risk of disease progression can be retreated 12 months after the first injection even if they are asymptomatic. This statement is supported by increasing evidence of chondroprotective properties of HA 16, 17, [50] [51] [52] [53] [54] [55] and hence can possibly postpone prosthetic surgery. 56 Of course, the management of risk factors is recommended during the remission period. The algorithm for retreatment decision in patients who were satisfied with previous VS is given in Figure 2 .
Benefits and limitations of the use of soluble biomarkers in patients treated with HA injections have also been discussed. The experts concluded that, with current knowledge, there is not enough evidence to use soluble biomarkers as decision tools for reinjection or for monitoring the effects treatment in the daily practice. However, the experts encourage the use of soluble biomarkers to investigate the effect of VS on joint tissue metabolism and to assess their role as surrogate biomarkers of clinical and/or imaging outcomes.
In conclusion, the EUROVISCO working group drew up a set of suggestions aimed to help practitioners in the decision of retreatment with VS in patients with knee OA who were previously treated with IA HA injections. The task force built 2 separate decision algorithms based on the clinical result (failure or success) of the previous treatment. In case of failure, the authors draw attention to the necessity of a rigorous clinical and radiological analysis, and to the use of VS in concordance with data from the evidence-based medicine. A lateral mid-patellar approach is to be preferred to anterior approach and imaging guidance must be used in difficult cases such as obese patients. In patients who previously improved with VS, retreatment can be considered as soon as pain recurs or increases again. However, in subjects with a high risk of progression, in young patients, early OA, professional sportsmen, VS retreatment can be considered systematically even in asymptomatic patients as there is compelling new evidence on HA to retard OA progression.
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